Skip to the page

Data / Drug companies / Lifsa Drugs LLC

Lifsa Drugs LLC: 9 products in the FDA NDC directory, labeler code 72336

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Lifsa Drugs LLC (labeler code 72336) lists 9 products in the FDA National Drug Code Directory, covering 8 finished drugs by generic name. By type: 9 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 1, 2025.

The request: Watch Lifsa Drugs LLC (FDA labeler code 72336): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
72336
Products in commercial distribution
9
Packages
10
Finished drugs by generic name
8
Prescription products
9
Over the counter products
0
Flagged as original packager
9 of 9 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
July 1, 1959
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)888.9%
New drug applications (NDA)111.1%

Products by type

TypeProductsShare
Prescription drugs9100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet666.7%
Capsule, liquid filled111.1%
Tablet, orally disintegrating111.1%
Solution111.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Diclofenac Potassium72336-432Capsule, liquid filledGeneric drugs (ANDA)May 1, 2025
Chlorzoxazone72336-225TabletGeneric drugs (ANDA)March 20, 2025
Glimepiride 3 mg72336-641TabletGeneric drugs (ANDA)August 20, 2024
Valsartan72336-910SolutionGeneric drugs (ANDA)April 4, 2022
Ondansetron72336-073Tablet, orally disintegratingGeneric drugs (ANDA)December 26, 2006
Metformin Hydrochloride72336-095TabletGeneric drugs (ANDA)January 24, 2002
Metformin Hydrochloride72336-064TabletGeneric drugs (ANDA)January 24, 2002
Tolmetin Sodium72336-118TabletGeneric drugs (ANDA)July 31, 1992
Marplan72336-032TabletNew drug applications (NDA)July 1, 1959

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.